Received Nov 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
COVID-19 infection; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19 infection) in a 70-year-old female patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. Concurrent medical conditions included Asthma (with severe asthma, it started before she had her Moderna COVID-19 vaccines and had it all her life). On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19 infection) (seriousness criterion hospitalization). At the time of the report, COVID-19 (COVID-19 infection) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medications were reported. It was reported that, the patient wanted to know the names of Moderna's current COVID-19 vaccines. She had always gotten Moderna and wanted another dose. She wanted to know which between mNEXSPIKE and Spikevax was best for her as someone who had severe asthma, which was started before she had her Moderna COVID-19 vaccines and had it all her life. She had a COVID-19 infection in the past and was hospitalized. The patient did not experience any additional symptoms/events. No treatment information was provided.; Reporter's Comments: Company Comment: The benefit-risk relationship of the product is not affected by this report.
Asthma (with severe asthma, it started before she had her Moderna COVID-19 vaccines and had it all her life)